Articles tagged with Cancer Patients
The Endocrine Society's Clinical Practice Guideline recommends long-term screening for growth disorders and pituitary hormone deficiencies in childhood cancer survivors who underwent radiation therapy. The guideline aims to detect endocrine disorders early and provide optimal patient care for this vulnerable population.
Researchers have found a new test that significantly improves the identification of bladder tumors likely to recur and progress. The test involves examining STAG2 gene expression in removed tumors, offering additional predictive discrimination.
Researchers identify epigenetic enzyme TET2 as a key player in controlling dormant tumor cells that can lead to cancer recurrence. A novel biomarker, 5-Hydroxymethylcytosine (5hmC), is also discovered to detect these treatment-resistant cells and predict patient outcomes.
A new regulatory axis involving the transcription factor Prox1 has been revealed to negatively regulate MMP14 protein levels, which plays a significant role in cancer progression and metastasis. This discovery provides new insights into the mechanisms governing MMP14's function in physiological processes such as wound healing.
Sanford Burnham Prebys Medical Discovery Institute has received four Padres Pedal the Cause collaborative grants to fund research projects in cancer and immunology. The projects aim to develop new insights into developing drugs and treatments designed to attack and kill cancer cells.
Researchers found no association between efavirenz and depression or suicidal ideation in Ugandan HIV patients. Efavirenz, a commonly used HIV cocktail worldwide, was previously linked to adverse psychiatric side effects in US and European populations.
A new smart probe developed by Tel Aviv University researchers can detect and visualize individual cancer cells in real-time, allowing surgeons to target specific tumor locations. The probe uses near-infrared technology to identify overproduced enzymes in cancer cells, guiding precise removal of malignant tissue.
Two Phase I/II clinical studies, PROter and PROfind, evaluate the safety and efficacy of radiolabeled PSMA-R2 for prostate cancer treatment. The trials assess tumor activity and patient response to treatment.
Scientists at the German Cancer Research Center have discovered a protein called TXNIP that controls the aging process. TXNIP inhibits thioredoxin-1, an enzyme that protects DNA from oxidative stress and slows down aging processes.
A Monash University study found that older people's reduced immune responses to cancer and vaccines are due to the accumulation of dysfunctional immune cells. The researchers discovered two types of T cells that lose their ability to fight diseases with age, leading to lower success rates for cancer immunotherapy in the elderly.
Researchers found that PIM-2 kinase negatively regulates T cell responses, while PIM-1 and PIM-3 positively regulate them. Inhibiting PIM-2 accelerated graft-versus-host disease (GVHD) in allogeneic bone marrow transplant, but also produced robust tumor immunity.
Researchers identified a new subtype of prostate cancer characterized by loss of the CDK12 gene, which was found to be more common in metastatic cases. Tumors with this alteration were responsive to immune checkpoint inhibitors, a type of immunotherapy treatment.
A new study from University Hospitals Connor Integrative Health Network reveals that improvisational music therapy can effectively manage acute pain and improve mood in adult patients with sickle cell disease. Music therapy, when actively engaged with a therapist, has a stronger impact on pain management than passive listening to music.
A collaborative effort has discovered molecular features of testicular germ cell cancers, identifying potential mutations and other molecular changes. The study found signs of duplicated DNA and defects in DNA methylation, which could inform future efforts to improve treatment decisions and help monitor patients for cancer recurrence.
Lutathera therapy has been shown to provide significantly longer time to deterioration of quality of life compared to hormone therapy alone, with median times of 28.8 months vs 6.1 months for global health status and 25.2 months vs 11.5 months for physical functioning.
Researchers found that long-term viral suppression significantly reduces cancer risk in aging HIV-positive individuals, with lower rates seen in patients with sustained suppression compared to those with early or no suppression. The study highlights the importance of viral suppression in preventing cancer and may inform strategies for ...
Researchers have discovered how p53 stops the development of lymphoma and potentially other cancers by targeting specific DNA repair genes. This new information could help doctors identify patients at risk and develop safer treatments.
The Immunoscore test accurately predicts tumor recurrence risk in patients with colon cancer, enabling intensified treatment after surgery. The test identifies two types of immune cells in the tumor and its invasive margin, providing a reliable estimation of disease progression.
A new study from Columbia University Irving Medical Center suggests that excess zinc in muscles contributes to cachexia, a debilitating muscle-wasting syndrome affecting 80% of advanced cancer patients. The discovery could pave the way for developing drugs to treat or prevent muscle wasting in cancer patients.
The Arizona Cancer and Evolution Center at ASU will use interdisciplinary approaches to understand cancer, leveraging evolutionary and ecological models to develop new treatments and management strategies. The center aims to advance fundamental understanding of cancer through innovative research efforts.
A rigorous study found that ethanol-lock therapy, widely used to reduce bloodstream infections, was ineffective in preventing new or recurring infections in young cancer patients with central venous catheters. The treatment was associated with increased complications, including catheter blockages and hospitalization.
The NCI-MATCH trial has released new findings on three arms of the trial, showing promise in patients with rare genetic changes. The study's results suggest that future studies could see more responses in populations with earlier-stage disease.
A new study published in JAMA found that increased follow-up testing of colorectal cancer patients does not improve survival rates. The study showed that patients who underwent surgery for colorectal cancer experienced the same five-year survival rate regardless of whether they received two or five follow-up tests.
Researchers at NCI developed a high-throughput method to identify mutations recognized by the immune system, leading to a complete response in a breast cancer patient. The treatment used tumor-infiltrating lymphocytes that specifically target tumor cell mutations, showing promise for treating common epithelial cancers.
A Phase II trial suggests that erdafitinib, an FGFR inhibitor, benefits patients with metastatic urothelial cancer harboring FGFR3 mutations. The therapy achieved a 40% overall response rate, including complete and partial responses, as well as stable disease in nearly half of patients.
A new study found that men with prostate cancer who experience urinary, bowel, or sexual dysfunction after treatment are more likely to experience emotional distress, which can lead to worsening function. The researchers emphasize the need for greater investment in psychosocial care to mitigate treatment side effects and improve qualit...
A recent study from the University of Pennsylvania School of Medicine found that rates of inherited mutations in genes other than BRCA1/2 are twice as high in breast cancer patients with a second primary cancer. The study also investigated polygenic risk scores, which were not strongly linked to an increased risk of cancer.
The article highlights conflicting guidance on opioid prescribing, potentially jeopardizing pain management for patients with cancer. Key areas of concern include CDC guideline recommendations that don't align with NCCN guidelines, and the lack of evidence for non-pharmacologic treatments to manage moderate to severe pain.
A new clinical trial is testing whether omega-3 capsules can stop bowel cancer from returning after liver surgery. The trial, funded by Yorkshire Cancer Research, involves 450 patients and investigates the effectiveness of a highly purified form of EPA.
Researchers at TGen and HCI are working together to combat bone metastatic breast cancer, a leading cause of pain and death for patients. By blocking the activity of RON kinase, they aim to prevent further damage to skeletal structures and enhance anti-tumor immunity.
A 2013 CLL patient achieved complete remission with a single CAR T cell infusion, sparking insights into the human genome and immune response that may enhance response rates. The successful treatment was linked to the specific location of the CAR gene within the patient's T cell DNA.
Supriya G. Mohile, an oncologist at the Wilmot Cancer Institute, has been named the winner of the B.J. Kennedy Award by ASCO for her work in geriatric oncology. The award recognizes her research and efforts to improve communication between doctors and older patients with cancer.
Researchers discovered a naturally occurring protein called apolipoprotein A-I binding protein (AIBP) that inhibits inflammatory response underlying chronic pain processing. A single spinal injection of AIBP alleviated chemotherapy pain in mice for two months with no side effects.
Researchers found that gut bacteria can control antitumor immune responses in the liver by regulating bile acid metabolism and NKT cell accumulation. This discovery has implications for understanding liver cancer mechanisms and potential therapeutic approaches.
A new study found that gentle stretching can reduce tumor size and improve immune response in a mouse model of breast cancer. The research suggests a link between stretching, inflammation resolution, and improved immune function.
Researchers at MD Anderson Cancer Center found that intense post-treatment surveillance does not improve detection of recurrence or overall survival in stage I, II, or III colorectal cancer. The study suggests that current guideline recommendations need to be reconsidered.
Two studies found that more frequent follow-up testing did not significantly impact mortality rates from any cause or colorectal cancer over five years. However, a related editorial suggests that current guidelines should be reevaluated in the context of these findings and potential harms associated with more frequent testing.
The Annual Report to the Nation on Cancer finds a decline in US cancer death rates among men and women of all racial and ethnic groups. Prostate cancer incidence has increased, while mortality has stabilized, with trends linked to changes in PSA screening.
Researchers developed a mouse model of luminal bladder cancer to study its therapeutic efficacy, focusing on checkpoint inhibitors and neo-antigens. The model revealed lower levels of immune cells in luminal tumors and differences in neo-antigen expression between subtypes.
A breath analysis test showed good diagnostic accuracy for esophagogastric cancer in a study of 335 patients, including those already diagnosed with the disease. The test identified abnormally regulated volatile organic compounds in the breath associated with esophagogastric cancer.
A federally funded trial found that using mobile and sensor technology reduced symptom severity in patients with head and neck cancer. The technology, called CYCORE, enabled remote monitoring of patient symptoms, allowing doctors to detect concerning symptoms early and respond more rapidly.
A study of 1,800 lung cancer screening sites found that only 1.9% of eligible heavy smokers were screened in 2016. Despite USPSTF and ASCO guidelines, low screening rates persist, with the South having the lowest rate at 1.6%. The study highlights the need for effective public service campaigns to encourage lung cancer screening.
Researchers have developed new treatment regimens that significantly boost survival rates for children and young adults with rare forms of leukemia and lymphoma, such as T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LL). The trial showed that 90% of patients lived at least four years after starting tre...
A meta-analysis of 20 randomised trials found that patients' sex may impact the efficacy of immunotherapy in cancer treatment. Women showed a lower survival benefit compared to men, regardless of cancer type and drug administered.
Next-generation sequencing (NGS) testing for all known lung cancer-related gene changes at diagnosis is more cost-effective and faster than testing one or a limited number of genes. This approach can save up to $2.1 million for Medicare and $250,000 for commercial insurance providers.
A randomized clinical trial found that acupuncture and cognitive behavioral therapy (CBT-I) decreased insomnia severity among cancer survivors, with CBT-I being more effective for those with mild symptoms. The study suggests that patients have more choices to manage their insomnia beyond traditional medicines.
Researchers found that patients with mutations in DNA repair genes like ATM and RB1 tend not to live as long as those without. These mutations can make tumor cells more susceptible to certain treatments, bringing potential hope for targeted therapies.
A new study published in Urologic Oncology suggests that MRI fusion biopsy is a more effective method for detecting clinically significant prostate cancer in patients with prior negative biopsies. The study analyzed data from over 700 patients and found that fusion biopsy detected 30.7% of clinically significant cancers, compared to 4....
Researchers have discovered universal antibodies that can recognize and neutralize a wide range of microorganisms, including bacteria, yeasts, and viruses. These breakthrough findings hold promise for developing new treatments for life-threatening infections, particularly in patients with weakened immune systems.
A new study examines clinical, functional, and neurophysiological outcomes in 121 long-term childhood cancer survivors. Chemotherapy-induced peripheral neuropathy can be a potentially long-lasting adverse effect of chemotherapy agents.
A new computational strategy simplifies complex cancer biomolecular data by emphasizing patient-to-patient variation in molecular signatures of cancer cells. This approach aims to provide a personalized treatment plan by analyzing the genetic makeup and impaired biological pathways of individual patients.
Researchers have developed criteria for routine genetic screening of patients with medulloblastoma, a rare and malignant tumor predominantly affecting children. This analysis of 1022 patients identified six genes frequently affected by genetic alterations, increasing cancer risk in up to 20% of the patient population.
A new study found that patients with low risk of local recurrence can safely undergo surgery alone without receiving chemoradiotherapy. This strategy could reduce the number of patients who receive chemoradiotherapy by half, with minimal risk of undertreatment.
A daily tablet has been shown to significantly reduce the risk of blood clots in cancer patients, with a lower rate of recurrence compared to traditional anticoagulant treatment. The study also found increased bleeding risks with the oral drug rivaroxaban.
Researchers developed a method to identify men with locally advanced prostate cancer who are less likely to respond well to radiotherapy. A 28-gene signature accurately identifies hypoxic tumour tissue in patients with prostate cancer that invades nearby structures. This signature could lead to improved treatment outcomes for patients.
A survey of over 200 oncologists reveals that most have discussed medical marijuana use with patients, but many lack knowledge on its effectiveness. The study highlights the need for clinical trials and education to inform cancer care.
A new AI method developed by MD Anderson researchers uses deep neural networks to automate the contouring of high-risk clinical target volumes in head and neck cancers. The model achieves comparable results to trained oncologists, offering a potential solution to reduce inter-physician variability and improve treatment efficiency.
A new phase 1 trial has shown that CAR T therapy CYAD-01 can induce a complete remission in a patient with acute myeloid leukemia, lasting nine months. This breakthrough is significant as it is the first time CAR T therapy has been effective without preconditioning chemotherapy.
Researchers have identified six genes associated with an increased risk of developing medulloblastoma, a common childhood brain tumor. Genetic screening guidelines have been developed to help patients understand their lifetime cancer risk and manage their care.
A new quality-control test developed by TGen can detect cancer in blood with high accuracy, filtering out contaminants and evaluating cfDNA samples. This test has shown promising results in several cancer types, including melanoma and breast cancer.